Physician profile
Robert A Watson
NPI 1417060286
$3,606.38
in general payments reported to CMS, 2019-2025
34 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $639 · 2021: $802 · 2022: $554 · 2023: $399 · 2024: $607 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.82 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $447.73 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $343.14 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Antares Pharma, INC. | $143.45 | 2022-2025 | Xyosted |
| Glaxosmithkline, LLC. | $132.42 | 2020-2023 | Trelegy Ellipta |
| Upsher-Smith Laboratories LLC | $114.96 | 2019-2020 | |
| Pfizer INC. | $109.95 | 2019-2025 | |
| Amgen INC. | $104.73 | 2019-2025 | Otezla, Repatha, Otezla |
| Braintree Laboratories, INC. | $101.91 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.53 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.55 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $89.92 | 2019-2024 | Farxiga |
| Allergan, INC. | $74.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.65 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.37 | 2024-2025 | Caplyta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.03 | 2021-2023 | Jardiance |
| Supernus Pharmaceuticals, INC. | $44.54 | 2020-2022 | |
| Abiomed | $44.00 | 2024 | Impella |
| Medtronic, INC. | $43.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.81 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $37.82 | 2022-2025 | Rexulti |
| Abbott Laboratories | $36.34 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $30.18 | 2025 | Imcivree |
| Horizon Therapeutics Plc | $29.37 | 2020-2022 | |
| Amarin Pharma, INC. | $23.34 | 2020 | |
| Astellas Pharma US INC | $19.59 | 2024 | Veozah |
| Shield Therapeutics INC | $19.40 | 2023 | Accrufer |
| Gilead Sciences, INC. | $16.45 | 2020 | |
| Eisai INC. | $15.67 | 2020 | |
| Currax Pharmaceuticals LLC | $14.17 | 2025 | Contrave, Onzetra Xsail |
| Dermira, INC. | $13.67 | 2019 | |
| Genentech USA, INC. | $12.36 | 2019 | |
| Esperion Therapeutics, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.